RxDoctor Payments Data

Amanda Foshee, MD

Family Medicine · Section, ALNPI 1487945309

Payments from drug & device makers

$1,014in general payments, 2019–2025

Across 51 payments — averaging $19.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$257
  • AstraZeneca$146
  • Lilly USA, LLC$135
  • Dexcom, Inc.$77
  • Johnson & Johnson$76
  • GSK$53
  • plus $270 from 9 others

What the payments were for

  • Food & beverage$1,014100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,014 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$8,444
Medicare patients
65
Services billed
165

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin114$64,442
EliquisApixaban91$58,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$50,099
OzempicSemaglutide45$46,634
MounjaroTirzepatide30$41,629
TrulicityDulaglutide32$32,034
JanuviaSitagliptin Phosphate60$30,073
FarxigaDapagliflozin Propanediol42$26,935
Tresiba Flextouch U-200Insulin Degludec15$15,997
XareltoRivaroxaban19$14,980
Humalog Kwikpen U-200Insulin Lispro12$14,500
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog20$14,499
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$13,361
Breztri AerosphereBudesonide/Glycopyr/Formoterol19$12,725
Tresiba Flextouch U-100Insulin Degludec19$10,260

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$135$73,66362 claims
PfizerEliquis$16$58,88891 claims
GSKTrelegy Ellipta$53$50,09949 claims
Novo NordiskOzempic$16$46,63445 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$146$42,57972 claims
Johnson & JohnsonXarelto$76$14,98019 claims
AbbVieLumigan$257$2,96711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Section

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →